Healthcare Archives - Page 15 of 17 - Boston Life Sciences Times

Obsidian Therapeutics Completes Galera Merger and $350 Million Financing

August 3, 2026

Sail Biomedicines, Johnson & Johnson Partner on In Vivo CAR-T Therapies

July 30, 2026

Synlogic, Caldera Therapeutics Agree to Merge in All-Stock Deal

July 29, 2026

THIS WEEK'S STORIES

Seaport Therapeutics Reports $62.6 Million Quarterly Loss, Advances Depression and Anxiety Programs

August 3, 2026

Bicycle Therapeutics Narrows Second-Quarter Loss, Extends Cash Runway Into 2030

July 30, 2026

Dash Bio Raises $30 Million Series A to Speed Drug Development

August 3, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Healthcare

Included Health to Acquire Firefly Health in Clinically Integrated Health Plan Deal

Employer Health Plan Costs Expected to Rise 9.9% in 2027, Segal Survey Finds

Norway Renews Nationwide Use of Wolters Kluwer’s UpToDate Platform

Element Care Appoints Current Health Founder Chris McGhee to Board

Form Health Begins Prescribing Through Medicare GLP-1 Bridge Program

Most Read

CREATE Medicines Cleared to Begin Phase 1/2 Trial of In Vivo CAR-T Therapy for Autoimmune Diseases

Insilico Medicine Launches AI Benchmark for Drug Discovery Models

Apnimed Prices Upsized IPO at $16 Per Share, Raising $192 Million

Decoy Therapeutics Expands Patent Portfolio for Antiviral Platform

EDITOR PICKS

Obsidian Therapeutics Completes Galera Merger and $350 Million Financing

Sail Biomedicines, Johnson & Johnson Partner on In Vivo CAR-T Therapies

Synlogic, Caldera Therapeutics Agree to Merge in All-Stock Deal

THIS WEEK'S STORIES

Seaport Therapeutics Reports $62.6 Million Quarterly Loss, Advances Depression and Anxiety Programs

Bicycle Therapeutics Narrows Second-Quarter Loss, Extends Cash Runway Into 2030

Dash Bio Raises $30 Million Series A to Speed Drug Development

POPULAR CATEGORY

ABOUT US

FOLLOW US